Clinical Trials


A Study on the Safety and Effectiveness of L-756423 Plus Indinavir in HIV-Positive Patients Who Have Previously Taken Indinavir

This study has been completed
Merck Sharp & Dohme Corp.

Information provided by (Responsible Party)
NIH AIDS Clinical Trials Information Service Identifier

First received: January 17, 2000
Last updated: June 23, 2005
Last Verified: February 2000
History of Changes


The purpose of this study is to see if L-756423, an anti-HIV drug, is safe to give with indinavir and if it works well at lowering the level of HIV in the blood (viral load).

Condition Intervention Phase
HIV Infections

Drug : L-756423
Drug : Indinavir sulfate
Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: A Multicenter, Open-Label, Pilot Study to Evaluate the Safety and Activity of L-756423/Indinavir Sulfate, 800/400 Mg b.i.d. in Combination With Two nRTIs in HIV-Infected Patients Who Failed an Indinavir Containing Regimen

Further study details as provided by NIH AIDS Clinical Trials Information Service:

Enrollment: 30

Detailed Description:

All patients receive L-756423 plus indinavir plus two licensed nucleoside reverse transcriptase inhibitors (NRTIs), at least one to which the patient is naive. Patients remain on the drug regimen for 12 weeks (with possible extension to 16 weeks). Patients are evaluated with physical examinations and laboratory tests for blood and urine at Weeks 1, 2, 4, 6, 8, and 12 and two weeks post study. Plasma viral RNA is measured at Weeks 1, 2, 4, 6, 8, and 12. CD4 cell counts are measured at Weeks 2,4,8, and 12.



Ages Eligible for Study: 18 Years and older  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: No  


Inclusion Criteria
You may be eligible for this study if you:

  • Are HIV-positive.
  • Are at least 18 years old.
  • Have a viral load of at least 1,000 copies/ml.
  • Have a CD4 cell count of at least 100 cells/mm3.
  • Have experienced treatment failure (your viral load increased significantly) within 24 weeks of study entry while taking indinavir.

  • Exclusion Criteria
    You will not be eligible for this study if you:
  • Are taking nonnucleoside reverse transcriptase inhibitors (NNRTIs).

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00002452


United States, Alabama
Univ of Alabama at Birmingham
Birmingham, Alabama, United States, 352942050
United States, District of Columbia
Georgetown Univ
Washington, District of Columbia, United States, 20007
United States, Georgia
AIDS Research Consortium of Atlanta
Atlanta, Georgia, United States, 30308
United States, Hawaii
Hawaii AIDS Clinical Trial Unit
Honolulu, Hawaii, United States, 96816
United States, Illinois
The CORE Ctr
Chicago, Illinois, United States, 60612
United States, New York
Cornell Clinical Trials Unit - Chelsea Clinic
New York, New York, United States, 10011
United States, Pennsylvania
Pittsburgh Treatment Ctr / Univ of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15261
United States, Tennessee
Vanderbilt Univ Med Ctr
Nashville, Tennessee, United States, 37203

Sponsors and Collaborators

Merck Sharp & Dohme Corp.
More Information

More Information

Responsible Party: Merck Sharp & Dohme Corp. Identifier: NCT00002452   History of Changes  
Other Study ID Numbers: 300A  
Study First Received: January 17, 2000  
Last Updated: June 23, 2005  

Keywords provided by NIH AIDS Clinical Trials Information Service:

Drug Therapy, Combination
HIV Protease Inhibitors
Reverse Transcriptase Inhibitors
Anti-HIV Agents
Viral Load

Additional relevant MeSH terms:
HIV Infections
Indinavir processed this data on September 21, 2018
This information is provided by